Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models

Documenti analoghi

• Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models
  di: Mayu Tomita, et al.
  Pubblicazione: (2026)
• Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
  di: Carrie van der Weyden, et al.
  Pubblicazione: (2025)
• Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR‐T Therapy
  di: Rafael Hernani, et al.
  Pubblicazione: (2025)
• Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study
  di: Neha Venkatesh, et al.
  Pubblicazione: (2026)
• Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
  di: Filippo Spriano, et al.
  Pubblicazione: (2026)